KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term ...
Hosted on MSN18d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Woman credits WVU Medicine for second chance at life after years of debilitating illness and misdiagnosis
A woman suffering debilitating symptoms is crediting WVU Medicine for giving her her life back after finally receiving a ...
BioCryst to present new ORLADEYO results from APeX-P pediatric trial
Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with ...
BioWorld13d
TGA clears CSL’s garadacimab to prevent hereditary angioedema
Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...
Healio27d
Lanadelumab increases attack-free rates in hereditary angioedema patients
Perspective from Douglas H. Jones, MD Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy ...
Optimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of Sebetralstat
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...
Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...